Civic Intelligence

The Cardiometabolic Disease Research Foundation

EIN 26-2118766 • 501(c)3 • Los Angeles, CA

Profile

Cardiometabolic disease research

823 S Bundy 107Los Angeles, CA 90049

n/A

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

Score unavailable

No value available

Liabilities-to-assets requires both liabilities and assets on the latest valid filing.

Source year 2021

Liabilities / Revenue

Score unavailable

No value available

Liabilities-to-revenue requires both liabilities and revenue on the latest valid filing.

Source year 2021

Net Margin

Score unavailable

No value available

Net margin requires both revenue and expenses on the latest valid filing.

Source year 2021

Top Officer Pay

81st percentile

$0

Higher top officer pay than 81% of similar nonprofits.

501(c)3 • <$500k nonprofits • Source year 2021

Asset Growth

10th percentile

-100%

Faster asset growth than 10% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Revenue Growth

3rd percentile

-100%

Faster revenue growth than 3% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Balance Sheet
Liabilities / AssetsScore unavailable

Assets

Down

$0

Down $9,550 (-100%) from 2020

Liabilities

-

No earlier filing loaded for comparison.

Net Assets

Down

$0

Down $9,550 (-100%) from 2020

Operations
Liabilities / RevenueScore unavailableNet MarginScore unavailable

Revenue

Down

$0

Down $28,200 (-100%) from 2020

Expenses

Down

$9,550

Down $19,706 (-67%) from 2020

Net Income

Down

-$9,550

Down $8,494 (-804%) from 2020

Trend Graphs

Balance Sheet Trend

Asset Growth10th percentile

Grouped bars show assets, liabilities, and net assets across loaded filings.

$150K$100K$50K$0Assets 2010: $24,249Net Assets 2010: $24,2492010Assets 2011: $97,970Liabilities 2011: $0Net Assets 2011: $97,9702011Assets 2012: $115,906Net Assets 2012: $115,9062012Assets 2013: $31,625Liabilities 2013: $0Net Assets 2013: $31,6252013Assets 2014: $13,538Net Assets 2014: $13,5382014Assets 2015: $115,770Liabilities 2015: $0Net Assets 2015: $115,7702015Assets 2016: $74,289Net Assets 2016: $74,2892016Assets 2017: $3,988Net Assets 2017: $3,9882017Assets 2018: $54,428Net Assets 2018: $54,4282018Assets 2019: $10,606Net Assets 2019: $10,6062019Assets 2020: $9,550Net Assets 2020: $9,5502020Assets 2021: $0Net Assets 2021: $02021

Highlighted filing

2021

Assets$0
Liabilities-
Net Assets$0
Open 2021 Filing

Operations Trend

Revenue Growth3rd percentile

Revenue, expenses, and net income by year, with the latest filing highlighted.

$400K$200K$0-$200KRevenue 2010: $155,142Expenses 2010: $148,538Net Income 2010: $6,6042010Revenue 2011: $90,664Expenses 2011: $16,048Net Income 2011: $74,6162011Revenue 2012: $68,635Expenses 2012: $52,069Net Income 2012: $16,5662012Revenue 2013: $283,659Expenses 2013: $367,940Net Income 2013: -$84,2812013Revenue 2014: $100,004Expenses 2014: $118,091Net Income 2014: -$18,0872014Revenue 2015: $217,007Expenses 2015: $114,776Net Income 2015: $102,2312015Revenue 2016: $84,292Expenses 2016: $125,773Net Income 2016: -$41,4812016Revenue 2017: $193,847Expenses 2017: $264,148Net Income 2017: -$70,3012017Revenue 2018: $152,518Expenses 2018: $102,078Net Income 2018: $50,4402018Revenue 2019: $143,452Expenses 2019: $187,274Net Income 2019: -$43,8222019Revenue 2020: $28,200Expenses 2020: $29,256Net Income 2020: -$1,0562020Revenue 2021: $0Expenses 2021: $9,550Net Income 2021: -$9,5502021

Highlighted filing

2021

Revenue$0
Expenses$9,550
Net Income-$9,550
Open 2021 Filing

Filings

Most recent year

2021 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$0
Liabilities
-
Net assets
$0
Revenue
$0
Expenses
$9,550
Net income
-$9,550
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2021Detailed filing. Detailed filing data is available for this year.$0.00$0.00$0.00$0.10$0.10
2020Detailed filing. Detailed filing data is available for this year.$0.10$0.10$0.28$0.29$0.01
2019Detailed filing. Detailed filing data is available for this year.$0.11$0.11$1.43$1.87$0.44
2018Detailed filing. Detailed filing data is available for this year.$0.54$0.54$1.53$1.02$0.50
2017Detailed filing. Detailed filing data is available for this year.$0.04$0.04$1.94$2.64$0.70
2016Detailed filing. Detailed filing data is available for this year.$0.74$0.74$0.84$1.26$0.41
2015Detailed filing. Detailed filing data is available for this year.$1.16$0.00$1.16$2.17$1.15$1.02
2014Detailed filing. Detailed filing data is available for this year.$0.14$0.14$1.00$1.18$0.18
2013Detailed filing. Detailed filing data is available for this year.$0.32$0.00$0.32$2.84$3.68$0.84
2012Facts available. Structured filing facts are available, but richer extracted sections are limited.$1.16$1.16$0.69$0.52$0.17
2011Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.98$0.00$0.98$0.91$0.16$0.75
2010Facts available. Structured filing facts are available, but richer extracted sections are limited.$0.24$0.24$1.55$1.49$0.07
Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2021 to Dec 31, 2021
Signed
May 4, 2022
Return Version
2021v4.0
Mission and Program Overview

Mission

Cardiometabolic disease research

Program Services

DescriptionGrantsExpenses
HUMAN EPICARDIAL FAT CYTOKINES AND CORONARY ATHEROSCLEROSIS: Research Grants given to a number of Universities that have Molecular Sciences and Medical Research Departments, currently with the Stanford University,University of Missouri in the United States, and the University of Nottingham, in the United Kingdom.In prior years with University of Indiana, and the University of Tennessee, Memphis,TN.Research. Dr, Harold S. Sacks collaborated with these Universities , which resulted in various medical papers being published in reputable medical journals.(Note Dr. Harold S. Sacks does not receive any grants, all grants are paid to the research entities mentioned above.)PRESIDENT'S PROPOSAL IN DECEMBER 2021:1. As recorded and in keeping with the minutes of the 2019/2020 meetings, the President scaled down funding in 2020 and 2021 by halting awards to Nottingham and MissouriUniversities but not Stanford nor UCLA. The Board members had advised the President that it was his prerogative to decide on the future research direction of the Foundation.Accordingly, at this meeting, the president advised the Board of his intention to terminate the Foundations activities on December 31,2021. He thanked all Board members for their advice and guidance as well as their important contributions to the administration of the Foundation and the attainment of its academic goals, especially the successful publication of 32 papers in top scientific journals from 2008 until 2021 from research made possible by funded Foundation projects. Members endorsed this plan and proposed a vote of thanks to the President for his work over the years. The President proposed to donate $7000.00 of the balance of accounts 7109.64 to Dr Tracey McLaughlins ongoing research on epicardial fat at Stanford University leaving $109.6 to cover expenses incurred in terminating the Foundations operations. This was accepted by the Board. 3. Research Activities: (i)Publications: In 2021, 2 new papers were published in peer-reviewed, highly rated medical journals. These 2 papers were added to the list of scientific papers generated from CDRF-funded projects from 2008 until 2021 now totaling 32 [See Appendix 1 included as part of the minutes]. (ii) Ongoing Projects: Due to the closure of the foundations activities on December 31,2021, no more projects will be funded$150$9,400
1. THE ITERACTIVE ROLE OF EPICARDIAL ADIPOSE TISSUE, HIGH-FAT DIET AND EXERCISE ON THE DEVELOPMENT OF CORONARY ARTERY DISEASE IN A SWINE MODEL OF HYPERCHOLESTROLEMIA.2. EFFECT OF EPICARDIAL FAT REMOVAL ON CORONARY ANTHESCLEROSIS IN PIGS.3. IMMUNO-HISTOCHEMICAL CHARACTERIZATION OF BROWN ADIPOCYTES IN HUMAN EPICARDIAL AND SUBCUTANEOUS FAT. Research Grants given to Biomedical Sciences Department, University of Missouri, Columbia, Missouri.Research, in collaboration with Dr. Harold S. Sacks, resulted in various medical papers being published in reputable medical journals.(Note Dr. Harold S. Sacks does not receive any grants, all grants are paid to the research entity mentioned above.)--
Research Activities:(i) Publications: Scientific papers accruing from funded projects dating from 2008 until 2016 were presented and added to the minutes as Appendix 1. (a) In 2016, 5 new papers were published in peer-reviewed medical journals with high impact numbers.It is anticipated that several scientific manuscripts will be submitted for publication in 2017. (b) Ongoing Projects:i) Vasomotor effects of perivascular adipose tissue: Role of UCP-1: ii) Interscapular brown fat pad nerve stimulation to increase energy expenditure in normal and diet-induced obese mice.In collaboration with Jaume Padilla PhD, University of Missouri. CDRF funding = $41603.iii) Identification of epigenetic regulators of epicardial adipose tissue development. In collaboration with Pablo Fainberg PhD and Mike Symonds PhD, University of Nottingham UK. Start date: 1st January 2016, End date: 31st December 2016.CDRF Funding = $86252.iv) Human epicardial fat and coronary atherosclerosis adjacent to the myocardial bridge. In collaboration with Tracey McLaughlin MS MD, Division of Endocrinology, Dept of Medicine, Stanford University. Start date October 2016. Funding $75000.(c) Completed Projects:In silico analysis of human epicardial adipose tissue during development.in collaboration with Pablo Fainberg PhD and Mike Symonds PhD, University of Nottingham UK. Start date: 1st August 2014, End date: 31st December 2015. CDRF Funding = $20000 per annum. Browning of white adipose tissue in patients with pheochromocytoma: in collaboration with UCLA departments of endocrine surgery and genetics. CDRF funding = $10,000.Epicardial Fat and coronary artery disease: in collaboration with Mike Sturek PhD, University of Indiana. CDRF funding = $331,020.--
Publications from Projects funded by the Cardiometabolic Disease Research Foundation: 2008-2016 1. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, Wolf RY, Carter RA, Tichansky DS.Identification of Omentin mRNA in human epicardial adipose tissue; comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obesity 32:810-815, 2008.2. Sacks HS, Johnson E. Adipokine concentrations are similar in femoral artery and coronary venous sinus blood: evidence against in vivo endocrine secretion by human epicardial fat. Adipobiology 1:51-56, 2009 3. Sacks HS, Fain JN, Holman B, Cheema P, Chary C, Parks F, Karas J , Optican R, Bahouth SW, Garrett E, Wolf RY, Carter RA, Robbins T, Wolford D, Samaha J. Uncoupling protein-1 and related mRNAs in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. J Clin Endoclinol Metab 94:3611-3615, 2009.4. Fain J, Sacks H, Bahouth S, Tichansky D, Madan A, Cheema P. Human epicardial adipokine mRNAs: comparisons with their expression in sub-sternal, subcutaneous and omental fat. Metabolism Clinical and Experimental 59:1379-1386, 2010.5. Company J, Booth F, Laughlin MH, Arce-Esquivel A, Sacks H, Bahouth SW, Fain J. Epicardial fat gene expression after aerobic exercise training in pigs with coronary atherosclerosis: relationship to visceral and subcutaneous fat. J Appl Physiol 109:1904-1912, 2010.6. Sacks HS, Fain J N, Cheema P, Karas J, Bahouth S, Garrett E, Wolf RY, Wolford D, Samaha J. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 34:730-733, 2011. 7. Sacks HS, Fain J N, Cheema P, Bahouth S, Garrett E, Wolf RY, Wolford D, Samaha J. Depot-specific over-expression of pro-inflammatory, redox, endothelial cell and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord 9: 433-439, 2011. 8. Fain JN, Company JM, Booth FM, Laughlin MH, Padilla J, Jenkins NT, Bahouth SW, Sacks HS. Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs. Metabolism Clinical Experimental, 62: 1503-1511, 2013. 9. Sacks HS, Fain JN, Bahouth SW, Ojha S, Frontini A, Budge H, Cinti S, Symonds ME. Human Epicardial Fat exhibits Beige Features. J Clin Endoclinol Metab 98:E1488-1455, 201310. Davies GR, Birtwistle M, Pope M, Perry V, Sacks H, Budge H, Symonds M The developmental transition of epicardial, paracardial and omental adipose tissue during early life in the sheep 201311. Schultz KA, McKenney ML, Boyd JH, Byrd JP, Alloosh M,Teague SD, Arce-Esquivel AA, Fain JN, Laughlin MH, Sacks HS, Sturek M. Epicardial adipose excision slows the progression of porcine coronary atherosclerosis. J Cardiothoracic Surg 9:2-11, 201412. Ojha S, Fainberg HP, Wilson V, Pelella G, Castellanos M, May ST, Lotto AA, Sacks H, Symonds ME, Budge H. Novel gene pathway identification during the development of human epicardial fat through early life. J Clin Invest Insight 1: 2016 [Human]13. Vergnes L, Davies GR, Lin JY, Yeh MW, Livhits MJ, Harari A, Symonds ME, Sacks HS, Reue K. Augmented adipocyte browning and mitochondrial function in peri-adrenal but not subcutaneous fat in pheochromocytoma J Clin Endocrinol Metab 2016 [Human]14. McKenney-Drake ML, Rodenbeck SD, Bruning RS, Kyle W. Yancey KW, Alloosh M, Sacks HS, Sturek M. Epicardial adipose tissue removal potentiates outward remodeling and arrests coronary atherogenesis. Ann Thor Surg 2016. [Pigs]15. Aldiss P, Davies G,Woods R,Budge H,Sacks HS, Symonds ME. Browning the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol 2016.[Review]16. Winn NC, Vieira-Potter VJ, Michelle L. Gastecki ML,Welly RJ, Scroggins RJ, Zidon TM, Gaines TL,ML, Karasseva NG, Kanaley JA, Sacks HS, Padilla J. Loss of UCP1 exacerbates Western diet-induced glycemic dysregulation independent of changes in body weight in female mice.Am J Physiol Regul Integr Comp Physiol 2016[mice]17. McKenney-Drake ML, Rodenbeck SD, Bruning RS, Kyle W. Yancey KW, Alloosh M, Sacks HS, Sturek M. Epicardial adipose tissue removal potentiates outward remodeling and arrests coronary atherogenesis. Ann Thor Surg 103:1622-1630, 2017 [Pigs].18. Winn NC, Vieira-Potter VJ, Michelle L. Gastecki ML,Welly RJ, Scroggins RJ, Zidon TM, Gaines TL,ML, Karasseva NG, Kanaley JA, Sacks HS, Padilla J. Loss of UCP1 exacerbates Western diet-induced glycemic dysregulation independent of changes in body weight in female mice.Am J Physiol Regul Integr Comp Physiol,312:R74-R84,2107 [mice] 19. Winn NC, Grunewald ZI, Gastecki ML, Woodford ML, Welly RJ, Clookey SL, Ball JR, Gaines TL, Karasseva NG, Kanaley JA, Sacks HS, Vieira-Potter VJ, Padilla J. Deletion of UCP1 enhances ex vivo aortic vasomotor function in female but not male mice despite similar susceptibility to metabolic dysfunction. Am J Physiol Endocrinol Metab. June 2017 [mice]20. Beyond obesity - Thermogenic adipocytes and cardiometabolic health. Aldiss P, Dellschaft N, Sacks HS, Budge H, Symonds ME. Horm Mol Biol Clin Invest 2017[review]21.Velickovic K, Lugo Leija HA, Bloor I, Law J, Sacks H, Symonds M, Sottile V. Low temperature exposure induces browning of bone marrow stem cell derived adipocytes in vitro. Sci Rep 8: 4974,2018[Mice and Human]. 322. Grunewald ZI, Winn NC, Gastecki ML, Woodford ML, Ball JR, Hansen SA, Sacks HS, Vieira-Potter VJ, Padilla J. Removal of interscapular brown adipose tissue increases aortic stiffness despite normal systemic glucose metabolism in mice. Am J Physiol Regul Integr Comp Physiol 314: R584-R597, 2018[Mice].23.Fainberg HP, Birtwistle M, Alagal R, Alhaddad A, Pope M, Davies G, Woods R, Castellanos M, May ST, Ortori CA, Barrett DA, Perry V, Wiens F, Stahl B, van der Beek E, Sacks H, Budge H, Symonds ME. Transcriptional analysis of adipose tissue during development reveals depot-specific responsiveness to maternal dietary supplementation. Sci Rep. 8:9628, 2018. [Sheep]24.Symonds ME, Aldiss P, Dellschaft N, Law J, Fainberg HP, Pope M, Sacks H, Budge H. Brown adipose tissue development and function and its impact on reproduction. J Endocrinol 238: R53-R62, 2018 [Review] 25.Clookey SL, Welly RJ, Zidon TM, Gastecki ML, Woodford ML, Grunewald ZI, Winn NC, Eaton D, Karasseva NG, Sacks HS, Padilla J, Vieira-Potter V. Increased susceptibility to OVX-associated metabolic dysfunction in UCP1-null mice. J Endocrinol 2018 [Mice]26.Winn NC, Acin-Perez R, Woodford ML, Hansen SA, Haney MM, Ayedun LA, Rector RS, Vieira-Potter VJ, Shirihai OS, Sacks HS, Kanaley JA, Padilla J. A Thermogenic-Like Brown Adipose Tissue Phenotype is Dispensable for Enhanced Glucose Tolerance in Female Mice. Diabetes 68;1717-1729, 2019 [Mice]27.Velickovic K, Wayne D, Leiji HAL, Bloor I, Morris DE, Law J, Budge H, Sacks H, Symonds ME, Sottile V. Caffeine exposure induces browning features in adipose tissue in vitro and in vivo. Sci. Rep 8:9104, 2019 [mice]28.Acin-Perez R, Benador IY, Petcherski A, Veliova M, Gloria A. Benavides GA, Lagarrigue S, Caudal A, Vergnes L, Murphy A, Karamanlidis G, Tian R, Reue K, Wanagat J, Sacks H, Amati F, Darley-Usmar FM, Liesa M, Divakaruni A, Stiles L, Shirihai OS.A novel approach to measure mitochondrial respiration in previously frozen biological samples .EMBO J 39:e 104073,2020. [Human]29. Leija HA, Velickovic K, Bloor I, Sacks H, Symonds ME, Sottile V. Cold-induced beigeing of stem cell-derived adipocytes is not fully reversible after return to normothermia. J Cell Mol Med. 2020 Sep 9. [mice]30.Velickovic K, Leija HA, Surrati A, Kim D-H, Sacks H, Symonds ME, Sottile V. Targeting glutamine synthesis inhibits adipogenic differentiation in vitro. Cell Physiol Biochem 54:917-927, 2020. [Mice]31.Acin-Perez R, Petcherski A, Veliova M, Benador IY, Assali A, Colleluori G,Cinti S, Brownstein AJ, Baghdasarian S, Livhits MJ, Yeh M, Krishnan KC, Vergnes L, Winn NC, Padilla J, Liesa M, Sacks HS, Shirihai OS. Redox Biology 46: 102087, 2021 [Human].32. McLaughlin T, Schnittger I, Nagy A, Zanley E, Xu Y, Song Y, Nieman K, Tremmel J, Dey D, Boyd J, Sacks H. Relationship Between Coronary Atheroma, Epicardial Adipose Tissue Inflammation, and Adipocyte Differentiation Across the Human Myocardial Bridge. J Am Heart Assoc.10:e021003. 2021[Human]--
Compensation and Service Providers
Top Officer Pay81st percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
HAROLD SACKS MDPresident & CEO-$0--
MARGARET A SACKSSecretary-$0--
MALCOLM D MYERSDirector-$0--
Rick Boxer MDDirector-$0--
Filing and Contact Details

Filer

Filer Name
The Cardiometabolic Disease Research
EIN
26-2118766
Phone
4248323080
Address
823 S BUNDY 107, LOS ANGELES, CA 90049

Signing Officer

Name
Harold Sacks Md
Title
President & CEO
Signed
2022-05-04
Discuss with paid preparer
Yes

Preparer

Firm
Malcolm D Myers CPA
Address
5390 ESTATE OFFICE DR STE 2, MEMPHIS, TN 38119
Preparer
Malcolm Myers CPA
Phone
9013749060
Supplemental Narrative

Additional Explanations

Grants and Similar Amounts Paid In Excess of $5,000.4

“Class of Activity: MEDICAL RESEARCH | Donee's Name: Stanford University | Donee's Address: 3172 Porter Drive, Palo Alto CA 94304 | Relationship of Donee: NONE | Cash Amount Given: $9400”

Other Expenses.1

“Closing expenses $95”

Other Expenses.2

“Bank charges $30”

Other Expenses.3

“Annual fee $25”

Raw XML Appendix143 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/BooksInCareOfDetail/PersonNm0HAROLD SACKS MD
IRS990EZ/BooksInCareOfDetail/PhoneNum04248323080
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt0823 S BUNDY
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0LOS ANGELES
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CA
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd0900497512
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt09550
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-9550
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/FinalReturnInd0X
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt09550
IRS990EZ/Form990TotalAssetsGrp/EOYAmt00
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrantsAndSimilarAmountsPaidAmt09400
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingCashInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt09550
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt09550
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt01.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt10.10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt20.10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt30.10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0HAROLD SACKS MD
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1MARGARET A SACKS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2MALCOLM D MYERS
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3Rick Boxer MD
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0President & CEO
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1Secretary
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Director
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0true
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt0150
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0CARDIOMETABOLIC DISEASE RESEARCH
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0HUMAN EPICARDIAL FAT CYTOKINES AND CORONARY ATHEROSCLEROSIS: Research Grants given to a number of Universities that have Molecular Sciences and Medical Research Departments, currently with the Stanford University,University of Missouri in the United States, and the University of Nottingham, in the United Kingdom.In prior years with University of Indiana, and the University of Tennessee, Memphis,TN.Research. Dr, Harold S. Sacks collaborated with these Universities , which resulted in various medical papers being published in reputable medical journals.(Note Dr. Harold S. Sacks does not receive any grants, all grants are paid to the research entities mentioned above.)PRESIDENT'S PROPOSAL IN DECEMBER 2021:1. As recorded and in keeping with the minutes of the 2019/2020 meetings, the President scaled down funding in 2020 and 2021 by halting awards to Nottingham and MissouriUniversities but not Stanford nor UCLA. The Board members had advised the President that it was his prerogative to decide on the future research direction of the Foundation.Accordingly, at this meeting, the president advised the Board of his intention to terminate the Foundations activities on December 31,2021. He thanked all Board members for their advice and guidance as well as their important contributions to the administration of the Foundation and the attainment of its academic goals, especially the successful publication of 32 papers in top scientific journals from 2008 until 2021 from research made possible by funded Foundation projects. Members endorsed this plan and proposed a vote of thanks to the President for his work over the years. The President proposed to donate $7000.00 of the balance of accounts 7109.64 to Dr Tracey McLaughlins ongoing research on epicardial fat at Stanford University leaving $109.6 to cover expenses incurred in terminating the Foundations operations. This was accepted by the Board. 3. Research Activities: (i)Publications: In 2021, 2 new papers were published in peer-reviewed, highly rated medical journals. These 2 papers were added to the list of scientific papers generated from CDRF-funded projects from 2008 until 2021 now totaling 32 [See Appendix 1 included as part of the minutes]. (ii) Ongoing Projects: Due to the closure of the foundations activities on December 31,2021, no more projects will be funded
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt11. THE ITERACTIVE ROLE OF EPICARDIAL ADIPOSE TISSUE, HIGH-FAT DIET AND EXERCISE ON THE DEVELOPMENT OF CORONARY ARTERY DISEASE IN A SWINE MODEL OF HYPERCHOLESTROLEMIA.2. EFFECT OF EPICARDIAL FAT REMOVAL ON CORONARY ANTHESCLEROSIS IN PIGS.3. IMMUNO-HISTOCHEMICAL CHARACTERIZATION OF BROWN ADIPOCYTES IN HUMAN EPICARDIAL AND SUBCUTANEOUS FAT. Research Grants given to Biomedical Sciences Department, University of Missouri, Columbia, Missouri.Research, in collaboration with Dr. Harold S. Sacks, resulted in various medical papers being published in reputable medical journals.(Note Dr. Harold S. Sacks does not receive any grants, all grants are paid to the research entity mentioned above.)
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt2Research Activities:(i) Publications: Scientific papers accruing from funded projects dating from 2008 until 2016 were presented and added to the minutes as Appendix 1. (a) In 2016, 5 new papers were published in peer-reviewed medical journals with high impact numbers.It is anticipated that several scientific manuscripts will be submitted for publication in 2017. (b) Ongoing Projects:i) Vasomotor effects of perivascular adipose tissue: Role of UCP-1: ii) Interscapular brown fat pad nerve stimulation to increase energy expenditure in normal and diet-induced obese mice.In collaboration with Jaume Padilla PhD, University of Missouri. CDRF funding = $41603.iii) Identification of epigenetic regulators of epicardial adipose tissue development. In collaboration with Pablo Fainberg PhD and Mike Symonds PhD, University of Nottingham UK. Start date: 1st January 2016, End date: 31st December 2016.CDRF Funding = $86252.iv) Human epicardial fat and coronary atherosclerosis adjacent to the myocardial bridge. In collaboration with Tracey McLaughlin MS MD, Division of Endocrinology, Dept of Medicine, Stanford University. Start date October 2016. Funding $75000.(c) Completed Projects:In silico analysis of human epicardial adipose tissue during development.in collaboration with Pablo Fainberg PhD and Mike Symonds PhD, University of Nottingham UK. Start date: 1st August 2014, End date: 31st December 2015. CDRF Funding = $20000 per annum. Browning of white adipose tissue in patients with pheochromocytoma: in collaboration with UCLA departments of endocrine surgery and genetics. CDRF funding = $10,000.Epicardial Fat and coronary artery disease: in collaboration with Mike Sturek PhD, University of Indiana. CDRF funding = $331,020.
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt3Publications from Projects funded by the Cardiometabolic Disease Research Foundation: 2008-2016 1. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, Wolf RY, Carter RA, Tichansky DS.Identification of Omentin mRNA in human epicardial adipose tissue; comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obesity 32:810-815, 2008.2. Sacks HS, Johnson E. Adipokine concentrations are similar in femoral artery and coronary venous sinus blood: evidence against in vivo endocrine secretion by human epicardial fat. Adipobiology 1:51-56, 2009 3. Sacks HS, Fain JN, Holman B, Cheema P, Chary C, Parks F, Karas J , Optican R, Bahouth SW, Garrett E, Wolf RY, Carter RA, Robbins T, Wolford D, Samaha J. Uncoupling protein-1 and related mRNAs in human epicardial and other adipose tissues: epicardial fat functioning as brown fat. J Clin Endoclinol Metab 94:3611-3615, 2009.4. Fain J, Sacks H, Bahouth S, Tichansky D, Madan A, Cheema P. Human epicardial adipokine mRNAs: comparisons with their expression in sub-sternal, subcutaneous and omental fat. Metabolism Clinical and Experimental 59:1379-1386, 2010.5. Company J, Booth F, Laughlin MH, Arce-Esquivel A, Sacks H, Bahouth SW, Fain J. Epicardial fat gene expression after aerobic exercise training in pigs with coronary atherosclerosis: relationship to visceral and subcutaneous fat. J Appl Physiol 109:1904-1912, 2010.6. Sacks HS, Fain J N, Cheema P, Karas J, Bahouth S, Garrett E, Wolf RY, Wolford D, Samaha J. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care 34:730-733, 2011. 7. Sacks HS, Fain J N, Cheema P, Bahouth S, Garrett E, Wolf RY, Wolford D, Samaha J. Depot-specific over-expression of pro-inflammatory, redox, endothelial cell and angiogenic genes in epicardial fat adjacent to severe stable coronary atherosclerosis. Metab Syndr Relat Disord 9: 433-439, 2011. 8. Fain JN, Company JM, Booth FM, Laughlin MH, Padilla J, Jenkins NT, Bahouth SW, Sacks HS. Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs. Metabolism Clinical Experimental, 62: 1503-1511, 2013. 9. Sacks HS, Fain JN, Bahouth SW, Ojha S, Frontini A, Budge H, Cinti S, Symonds ME. Human Epicardial Fat exhibits Beige Features. J Clin Endoclinol Metab 98:E1488-1455, 201310. Davies GR, Birtwistle M, Pope M, Perry V, Sacks H, Budge H, Symonds M The developmental transition of epicardial, paracardial and omental adipose tissue during early life in the sheep 201311. Schultz KA, McKenney ML, Boyd JH, Byrd JP, Alloosh M,Teague SD, Arce-Esquivel AA, Fain JN, Laughlin MH, Sacks HS, Sturek M. Epicardial adipose excision slows the progression of porcine coronary atherosclerosis. J Cardiothoracic Surg 9:2-11, 201412. Ojha S, Fainberg HP, Wilson V, Pelella G, Castellanos M, May ST, Lotto AA, Sacks H, Symonds ME, Budge H. Novel gene pathway identification during the development of human epicardial fat through early life. J Clin Invest Insight 1: 2016 [Human]13. Vergnes L, Davies GR, Lin JY, Yeh MW, Livhits MJ, Harari A, Symonds ME, Sacks HS, Reue K. Augmented adipocyte browning and mitochondrial function in peri-adrenal but not subcutaneous fat in pheochromocytoma J Clin Endocrinol Metab 2016 [Human]14. McKenney-Drake ML, Rodenbeck SD, Bruning RS, Kyle W. Yancey KW, Alloosh M, Sacks HS, Sturek M. Epicardial adipose tissue removal potentiates outward remodeling and arrests coronary atherogenesis. Ann Thor Surg 2016. [Pigs]15. Aldiss P, Davies G,Woods R,Budge H,Sacks HS, Symonds ME. Browning the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol 2016.[Review]16. Winn NC, Vieira-Potter VJ, Michelle L. Gastecki ML,Welly RJ, Scroggins RJ, Zidon TM, Gaines TL,ML, Karasseva NG, Kanaley JA, Sacks HS, Padilla J. Loss of UCP1 exacerbates Western diet-induced glycemic dysregulation independent of changes in bo
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt0150
IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt09400
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt09550
IRS990EZ/TotalProgramServiceExpensesAmt0150
IRS990EZ/TotalRevenueAmt00
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/TypeOfOrganizationOtherInd0X
IRS990EZ/WebsiteAddressTxt0N/A
IRS990ScheduleA/HospitalNameAndAddressGrp/CityNm0Palo Alto
IRS990ScheduleA/HospitalNameAndAddressGrp/StateAbbreviationCd0CA
IRS990ScheduleA/HospitalNameAndAddressGrp/SupportedOrganizationName/BusinessNameLine1Txt0Stanford University Med Center
IRS990ScheduleA/MedicalResearchOrganizationInd0X
IRS990ScheduleN/AssetsDistributedInd0true
IRS990ScheduleN/AttorneyGeneralNotifiedInd0false
IRS990ScheduleN/BondLiabilitiesDischargedInd0false
IRS990ScheduleN/BondsOutstandingInd0false
IRS990ScheduleN/DirectorOfSuccessorInd0false
IRS990ScheduleN/EmployeeOfSuccessorInd0false
IRS990ScheduleN/LiabilitiesPaidInd0true
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/AssetsDistriOrExpnssPaidDesc0Cash Grants on 8/20/2021 & 12/7/2021
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/DistributionDt02021-12-07
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/FairMarketValueOfAssetAmt09400
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/MethodOfFMVDeterminationTxt0CASH GRANTS
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/AddressLine1Txt0Stanford University Med Center
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/CityNm0PALO ALTO
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/StateAbbreviationCd0CA
IRS990ScheduleN/LiquidationOfAssetsTableGrp/LiquidationOfAssetsDetail/USAddress/ZIPCd094305
IRS990ScheduleN/OwnerOfSuccessorInd0false
IRS990ScheduleN/ReceiveCompensationInd0false
IRS990ScheduleN/RequiredToNotifyAGInd0false
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Class of Activity: MEDICAL RESEARCH | Donee's Name: Stanford University | Donee's Address: 3172 Porter Drive, Palo Alto CA 94304 | Relationship of Donee: NONE | Cash Amount Given: $9400
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Closing expenses $95
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2Bank charges $30
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3Annual fee $25
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Grants and Similar Amounts Paid In Excess of $5,000.4
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Expenses.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Other Expenses.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Other Expenses.3
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/AuthenticationAssuranceLevelCd0AAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/FederatedAssuranceLevelCd0FAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/IdentityAssuranceLevelCd0IAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/TrustedCustomerCd02
ReturnHeader/BuildTS02022-09-23 18:48:47Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0HAROLD SACKS MD
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0President & CEO
ReturnHeader/BusinessOfficerGrp/SignatureDt02022-05-04
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0THE CARDIOMETABOLIC DISEASE RESEARCH
ReturnHeader/Filer/BusinessName/BusinessNameLine2Txt0FOUNDATION
ReturnHeader/Filer/BusinessNameControlTxt0CARD
ReturnHeader/Filer/EIN0262118766
ReturnHeader/Filer/PhoneNum04248323080
ReturnHeader/Filer/USAddress/AddressLine1Txt0823 S BUNDY 107
ReturnHeader/Filer/USAddress/CityNm0LOS ANGELES
ReturnHeader/Filer/USAddress/StateAbbreviationCd0CA
ReturnHeader/Filer/USAddress/ZIPCd090049
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0MALCOLM D MYERS CPA
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt05390 ESTATE OFFICE DR STE 2
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0MEMPHIS
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0TN
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd038119
ReturnHeader/PreparerPersonGrp/PhoneNum09013749060
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0Malcolm Myers CPA
ReturnHeader/PreparerPersonGrp/SelfEmployedInd0X
ReturnHeader/ReturnTs02022-05-04T10:21:53-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm0HAROLD SACKS
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm0MD
ReturnHeader/TaxPeriodBeginDt02021-01-01
ReturnHeader/TaxPeriodEndDt02021-12-31
ReturnHeader/TaxYr02021

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Peer Organizations

Similar nonprofits based on the same Siviq industry and scale cohort. 501(c)3 • <$500k nonprofits